Lekanumab and De-Nanomab: A Comparison

De-nanomab is not even FDA-approved yet, we're assuming it will be. Lily stratified patients based upon who they expected to benefit the most from this drug. Patients with high levels of tau were excluded because that would suggest more advanced or more rapidly progressing Alzheimer's disease. The headline number of slowing cognitive decline was better in the de-nanomAB study than it was in the Lekanumab study.